Investors House reported Q3 2024 revenue of EUR 2.4m, 10% below our estimate, while net operating in...
Nettoomsättningen för det tredje kvartalet uppgick till 113,8 MSEK (97,5), vilket motsvarade en orga...
FX/Other hampered the results, underlying in line Crypto rallying, we raise adj.
STENOCARE A/S (“STENOCARE” or the “Company”) continues to experience tough market conditions in Denm...
Redeye comments on the new ALG.APV-527 phase I data.
Europe recovered and FY guidance kept EBITA cut 2-4%, eyes starting to shift to 2025e Higher organic...
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and recent events...
Redeye leaves a comment on Faron’s recent pipeline update, suggesting that the company may look to e...
SinterCast redovisade en omsättning och bruttomarginal som var lägre än väntat.
AAC Clyde Space (AAC) remains an interesting avenue into the fast-growing low Earth orbital space se...
Solid Q3 report, adj. EBITA +9% y-o-y Price hikes in Q4 to benefit margins '25e-'26e EBITA +1%, 12x-...
Redeye states that the Q3 report came in below our estimates on both sales and EBITDA.
Redeye shares its initial comments on Kontigo Care’s Q3 2024 results, which showed slight positive d...
Investors House reported Q3 revenues of EUR 2.4m, 10% below our EUR 2.
Redeye makes minor estimate changes following Arise’s Q3 report, due Thursday last week.
Redeye provides its comment on Mendus’ Q3 2024 report.
Redeye updates its estimates and valuation following Serstech's Q3 2024 report.
Redeye comments on Lifeclean’s order from a defense authority in a European country.
Refine Group (”Refine”, ”koncernen” eller ”bolaget”) publicerade den 8 november 2024 bolagets delårs...
Minor estimate changes in absolute terms Restructuring likely to carry full effect in H2'25e '25e-'2...